Actively Recruiting
Ovarian Cancer Radiomics Approach in CT Led Evaluation
Led by Imperial College Healthcare NHS Trust · Updated on 2025-06-27
168
Participants Needed
1
Research Sites
359 weeks
Total Duration
On this page
Sponsors
I
Imperial College Healthcare NHS Trust
Lead Sponsor
N
National Cancer Center, Korea
Collaborating Sponsor
AI-Summary
What this Trial Is About
When patients have suspected or confirmed ovarian cancer standard treatment will involve surgery and chemotherapy. However, as with any treatment, it is challenging to predict treatment response in advance. Before treatment, all patients have a CT scan to describe where the cancer is in order to guide the treatment. There is now a new way to analyse routine scans using advanced computing methods, which may give more information about the ovarian cancer. This is called radiomics which analyses features in scans that are not visible to the naked eye. Our group at Imperial College London has worked on developing radiomic models to better understand ovarian cancer. This study aims to determine whether the information gained from this new approach would help us to tailor patient treatment plans to better meet the patient's individual needs, even more than done already. Furthermore, the aim is to understand how different types of ovarian cancer can correlate with the radiomic findings, which may help develop potential treatments in the future.
CONDITIONS
Official Title
Ovarian Cancer Radiomics Approach in CT Led Evaluation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Written (signed and dated) informed consent
- Age 18 years or over
- Suspected or confirmed advanced epithelial ovarian cancer (FIGO stage 3B or more)
- Being considered for active anticancer treatment such as primary cytoreductive surgery followed by chemotherapy or neoadjuvant chemotherapy followed by interval cytoreductive surgery
- Evaluable baseline portal venous phase CT scan before surgical or medical treatment for ovarian cancer
- Disease visible on pre-treatment portal venous phase baseline CT scan of 2 cm or larger
You will not qualify if you...
- Known contraindication to CT with intravenous contrast (e.g., contrast allergy, kidney failure, inability to lie flat)
- Unable to give informed consent
- Known pregnancy
- No visible disease smaller than 2 cm on portal venous phase baseline CT scan
- Previous surgery for removal of an adnexal mass
- Significant artifact on CT images, for example from metal prostheses, preventing meaningful disease segmentation
- Only suitable for palliative care at first presentation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Imperial College NHS Healthcare Trust
London, United Kingdom
Actively Recruiting
Research Team
C
Christina Fotopoulou, MD, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here